Medical Oncology

, Volume 21, Issue 1, pp 67–72

Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma

Original Article


In patients with non-Hodgkin’s lymphoma (NHL), there are some well-known tumor-related adverse prognostic factors that may increase the mortality rate. However, secondary factors such as viral hepatitis carriers that may decrease the cure rates are usually ignored. Reactivation of hepatitis B virus (HBV) infection in patients undergoing cytotoxic treatment for NHL is a well-known complication. Charts of 112 patients with NHL were retrospectively analyzed regarding their hepatitis serology, the indirect effects of seropositivity on disease outcome, and the precautions undertaken in these seropositive patients with NHL. Twelve patients (11%) with HBsAg positivity and two patients (1.7%) with antibody to hepatitis C virus positivity were detected. Eight out of 12 patients (67%) with HBsAg positivity and two patients (50%) with anti-HCV positivity showed reactivation of hepatitis during treatment of NHL. No reactivation was detected in four patients seropositive for HBV, who were given lamivudine prophylaxis before the initiation of chemotherapy schedules. Among patients with hepatitis reactivation, two were treated with lamivudine resulting in dramatic improvement and clinical remission of the disease. The remaining six patients with reactivation were left untreated, resulting in four deaths (67%) due to liver failure secondary to HBV and two deaths secondary to delayed treatment of NHL. One patient seropositive for anti-HCV also developed chronic hepatitis C. Determination of hepatitis serology in all patients with NHL before any chemotherapy administration is crucial, but insufficient, if not taken into consideration. In seropositive patients, HBV DNA should be determined and antiviral prophylaxis with lamivudine should be initiated before any treatment.

Key Words

Non-Hodgkin’s lymphoma hepatitis B virus reactivation chemotherapy lamivudine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lau JYN, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73:911–917.PubMedGoogle Scholar
  2. 2.
    Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TW, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100:182–188.PubMedGoogle Scholar
  3. 3.
    Soh LT, Ang PT, Chua EJ, Ong YW. Fulminant hepatic failure in Non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer 1992;28A:1338–1339.PubMedCrossRefGoogle Scholar
  4. 4.
    Wands JR. Subacute and chronic active hepatitis after with-drawal of chemotherapy. Lancet 1975;2:979.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoofnagle JH, Dusheiko GM, Schafer DF. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447–449.PubMedGoogle Scholar
  6. 6.
    Clark FL, Drummond MW, Chambers S, Champman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade Non-Hodgkin lymphoma. Ann Oncol 1998;9:385–387.PubMedCrossRefGoogle Scholar
  7. 7.
    Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 1999;78:247–249.PubMedCrossRefGoogle Scholar
  8. 8.
    Musolino C, Campo S, Pollicino T, Squadrito G, Spatari G, Raimondo G. Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin lymphoma and without liver disease. Haematologica 1996;81:162–164.PubMedGoogle Scholar
  9. 9.
    Gasztonyi B, et al. Hepatitis C virus infection associated with B-cell non-Hodgkin lymphoma in Hungarian patients. Br J Haematol 2000;110:497–498.PubMedGoogle Scholar
  10. 10.
    De Rosa G, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 1997;55:77–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Persico M, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724–725.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaneko S, Miller RH, Feinstone SM, Hoofnagle JH, Purcell RH. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Gastroenterology 1990;99:799–804.PubMedGoogle Scholar
  13. 13.
    Kumagai K, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(suppl 1): 107–109.PubMedCrossRefGoogle Scholar
  14. 14.
    Nokamura V, Motokura T, Fujita A, Vamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer 1996;78:2270–2275.Google Scholar
  15. 15.
    Yeo W, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J Med Virol 2000;62:299–307.PubMedCrossRefGoogle Scholar
  16. 16.
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925–2930.PubMedGoogle Scholar
  17. 17.
    Kawai Y, et al. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin’s lymphoma: case report and review of the literature. Ann Hematol 2001;80:482–484.PubMedCrossRefGoogle Scholar
  18. 18.
    Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumato S. Reactivation of precore mutant hepatitis virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992;37:1253–1259.PubMedCrossRefGoogle Scholar
  19. 19.
    Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999;94:249–251.PubMedCrossRefGoogle Scholar
  20. 20.
    Yeo W, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263–269.PubMedCrossRefGoogle Scholar
  21. 21.
    Silvestri F, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000;108:394–396.PubMedCrossRefGoogle Scholar
  22. 22.
    Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin lymphoma. Ann Hematol 2001;81:48–49.PubMedGoogle Scholar
  23. 23.
    Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 2002;116:166–169.PubMedCrossRefGoogle Scholar
  24. 24.
    Saif MW, Little RF, Hamilton JM, Allegra CJ, Wilson WH. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A case report and review of the literature. Ann Oncol 2001;12:123–129.PubMedCrossRefGoogle Scholar
  25. 25.
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657–1661.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai CL, et al. A one-year course of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61–68.PubMedCrossRefGoogle Scholar
  28. 28.
    Ohtsu T, Sai T, Oka M, Sugai Y, Tobiani K. Activation of hepatitis B virus carriers with hematological malignancies. Jpn J Clin Oncol 1991;21:360.PubMedGoogle Scholar
  29. 29.
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin’s lymphoma. Blood 1996;87:1202.PubMedGoogle Scholar
  30. 30.
    Chemotherapy and hepatitis B (editorial). Lancet 1989;2:1136–1137.Google Scholar
  31. 31.
    Vento S, Cainelli F, Mirandola F, Cosco L, Di Peri G, Solbiati M. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92–93.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2004

Authors and Affiliations

  • M. Ozguroglu
    • 1
  • A. Bilici
    • 2
  • H. Turna
    • 1
  • S. Serdengecti
    • 1
  1. 1.Department of Internal MedicineSection of Medical OncologyTurkey
  2. 2.Department of Internal Medicine, Cerrahpasa Medical FacultyIstanbul UniversityIstanbulTurkey
  3. 3.Çiçekçi Bostan Sok.Mesa Koru Evleri C1/1, AltunizadeIstanbulTurkey

Personalised recommendations